

# **Tata Chemicals North America Inc. and Subsidiaries**

**Consolidated Financial Statements and  
Independent Auditors' Report  
March 31, 2026 and 2025**

**Tata Chemicals North America Inc. and Subsidiaries**  
**Index**  
**March 31, 2026 and 2025**

---

	<b>Page(s)</b>
<b>Independent Auditors' Report</b> .....	1
<b>Consolidated Financial Statements</b>	
Statements of Income.....	3
Statements of Comprehensive Income.....	4
Balance Sheets.....	5
Statements of Changes in Stockholder's Equity.....	6
Statements of Cash Flows.....	7
Notes to Consolidated Financial Statements.....	8-31



KPMG LLP  
Suite 800  
1225 17th Street  
Denver, CO 80202-5598

## Independent Auditors' Report

Board of Directors  
Tata Chemicals North America, Inc.:

### *Opinion*

We have audited the consolidated financial statements of Tata Chemicals North America, Inc. and its subsidiaries (the Company), which comprise the consolidated balance sheets as of March 31, 2026 and March 31, 2025, and the related consolidated statements of income, comprehensive income, changes in stockholders' equity, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2026 and March 31, 2025, and the results of its operations and its cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.

### *Basis for Opinion*

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### *Responsibilities of Management for the Consolidated Financial Statements*

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with U.S. generally accepted accounting principles, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date that the consolidated financial statements are available to be issued.

### *Auditors' Responsibilities for the Audit of the Consolidated Financial Statements*

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.



In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

*KPMG LLP*

Denver, Colorado  
May 26, 2026

**Tata Chemicals North America Inc. and Subsidiaries**  
**Consolidated Statements of Income**  
**Years Ended March 31, 2026 and 2025**

---

<i>(in thousands)</i>	<u>2026</u>	<u>2025</u>
Net revenues	\$ 558,678	\$ 621,966
Cost of revenues - excluding depreciation	505,078	522,122
Cost of revenues - depreciation	<u>44,138</u>	<u>41,027</u>
Total cost of revenues	549,216	563,149
Selling, general and administrative expense	20,391	21,886
Loss on disposition of long-lived assets	<u>489</u>	<u>1,432</u>
Operating (expense) income	(11,418)	35,499
Interest expense, net	15,816	15,942
Goodwill Impairment	225,000	-
Other income, net	<u>(2,718)</u>	<u>(762)</u>
(Loss) income before income tax	(249,516)	20,319
Income tax expense (benefit)	<u>13,612</u>	<u>(546)</u>
Net (loss) income	(263,128)	20,865
Net income attributable to noncontrolling interest	<u>11,219</u>	<u>11,302</u>
Net (loss) income attributable to Tata Chemicals North America Inc.	<u><u>\$(274,347)</u></u>	<u><u>\$ 9,563</u></u>

See notes to consolidated financial statements.

**Tata Chemicals North America Inc. and Subsidiaries**  
**Consolidated Statements of Comprehensive Income**  
**Years Ended March 31, 2026 and 2025**

---

	<u>2026</u>	<u>2025</u>
<i>(in thousands)</i>		
Net (loss) income	\$(263,128)	\$ 20,865
Other comprehensive (loss) income, net of tax expense		
Defined benefit plan and other adjustments, net of tax of \$(1,921) and \$531	9,510	(1,899)
Unrealized gain (loss) on natural gas hedge, net of tax \$613 and \$(1,551)	(3,025)	7,670
Interest rate swap, net of tax of \$0 and \$234	<u>-</u>	<u>(847)</u>
Other comprehensive income	6,485	4,924
Net comprehensive (loss) income	(256,643)	25,789
Less: Net comprehensive income attributable to the noncontrolling interest	<u>11,219</u>	<u>11,302</u>
Net comprehensive (loss) income attributable to Tata Chemicals North America Inc.	<u><u>\$(267,862)</u></u>	<u><u>\$ 14,487</u></u>

See notes to consolidated financial statements.

**Tata Chemicals North America Inc. and Subsidiaries**  
**Consolidated Balance Sheets**  
**March 31, 2026 and 2025**

	<u>2026</u>	<u>2025</u>
<i>(in thousands, except share data)</i>		
<b>Assets</b>		
Current assets		
Cash and cash equivalents	\$ 20,648	\$ 37,888
Receivables, net of allowance for credit losses of \$895 and \$895	112,747	101,696
Income tax receivable	144	-
Inventories	35,961	36,405
Prepaid expenses and other current assets	<u>18,858</u>	<u>22,976</u>
Total current assets	188,358	198,965
Property, plant, and equipment, net	329,641	331,511
Goodwill	743,065	968,065
Deferred tax assets, net	-	9,109
Other assets	<u>25,801</u>	<u>23,197</u>
Total assets	<u>\$ 1,286,865</u>	<u>\$ 1,530,847</u>
<b>Liabilities</b>		
Current liabilities		
Accounts payable	\$ 40,465	\$ 59,953
Current portion of long-term debt	81,808	49,000
Current portion of finance lease obligation	10,829	10,013
Accrued liabilities	<u>32,554</u>	<u>28,193</u>
Total current liabilities	165,656	147,159
Finance lease obligation, net of current portion	27,312	33,748
Deferred tax liabilities, net	4,642	-
Other liabilities	62,748	80,958
Long-term debt, net of current portion	<u>194,432</u>	<u>194,045</u>
Total liabilities	<u>454,790</u>	<u>455,910</u>
<b>Stockholder's Equity</b>		
Tata Chemicals North America Inc. equity:		
Common stock, \$0.01 par value; 1,000 shares authorized		
100 shares issued and outstanding at		
March 31, 2026 and March 31, 2025	-	-
Additional paid-in capital	660,838	635,838
Accumulated other comprehensive income	20,644	14,159
Retained earnings	<u>150,593</u>	<u>424,940</u>
Total equity	<u>832,075</u>	<u>1,074,937</u>
Total liabilities and stockholder's equity	<u>\$ 1,286,865</u>	<u>\$ 1,530,847</u>

See notes to consolidated financial statements.

**Tata Chemicals North America Inc. and Subsidiaries**  
**Consolidated Statements of Changes in Stockholder's Equity**  
**Years Ended March 31, 2026 and 2025**

(in thousands)	Shares	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Total Stockholder's Equity	Noncontrolling Interest	Total Equity
<b>Balance—March 31, 2024</b>	100	\$ -	\$ 635,838	\$ 9,235	\$ 415,377	\$ 1,060,450	\$ -	\$ 1,060,450
Net Income	-	-	-	-	9,563	9,563	11,302	20,865
Distribution to noncontrolling interest	-	-	-	-	-	-	(11,302)	(11,302)
Other comprehensive income	-	-	-	4,924	-	4,924	-	4,924
<b>Balance—March 31, 2025</b>	<u>100</u>	<u>\$ -</u>	<u>\$ 635,838</u>	<u>\$ 14,159</u>	<u>\$ 424,940</u>	<u>\$ 1,074,937</u>	<u>\$ -</u>	<u>\$ 1,074,937</u>
Net (Loss) Income	-	-	-	-	(274,347)	(274,347)	11,219	(263,128)
Capital Contributions	-	-	25,000	-	-	25,000	-	25,000
Distribution to noncontrolling interest	-	-	-	-	-	-	(11,219)	(11,219)
Other comprehensive income	-	-	-	6,485	-	6,485	-	6,485
<b>Balance—March 31, 2026</b>	<u>100</u>	<u>\$ -</u>	<u>\$ 660,838</u>	<u>\$ 20,644</u>	<u>\$ 150,593</u>	<u>\$ 832,075</u>	<u>\$ -</u>	<u>\$ 832,075</u>

See notes to consolidated financial statements.

**Tata Chemicals North America Inc. and Subsidiaries**  
**Consolidated Statements of Cash Flows**  
**Years Ended March 31, 2026 and 2025**

	<b>2026</b>	<b>2025</b>
<i>(in thousands)</i>		
<b>Cash flows from operating activities</b>		
Net (loss) income	\$ (263,128)	\$ 20,865
Adjustments to reconcile net income to net cash provided by operating activities		
Depreciation and amortization	44,138	41,027
Amortization of financing fees	387	1,542
Deferred tax provision	12,444	(1,816)
Asset retirement obligation accretion	1,677	1,393
Impairment of goodwill	225,000	-
Loss on disposal of assets	489	1,432
Changes in assets and liabilities		
Increase in receivables from trade	(11,051)	(15,261)
(Decrease) increase in income taxes	(144)	384
Decrease in inventories	444	888
(Decrease) increase in accounts payable	(21,054)	4,016
Increase in accrued liabilities	723	697
Decrease in other liabilities	(8,459)	(5,098)
Decrease (increase) in prepaid expenses and other current and non-current assets	1,515	(10,692)
Net cash (used in) provided by operating activities	(17,019)	39,377
<b>Cash flows from investing activities</b>		
Capital expenditures	(36,263)	(61,791)
Net cash used in investing activities	(36,263)	(61,791)
<b>Cash flows from financing activities</b>		
Repayment of debt	(55,885)	(95,164)
New borrowings	88,693	144,000
Finance lease payments	(10,547)	(9,789)
Financing fees paid	-	(428)
Capital contributions	25,000	-
Distributions to noncontrolling interest	(11,219)	(11,302)
Net cash provided by financing activities	36,042	27,317
Change in cash and cash equivalents	(17,240)	4,903
<b>Cash and cash equivalents</b>		
Beginning of year	37,888	32,985
End of year	\$ 20,648	\$ 37,888
<b>Supplemental information</b>		
Cash paid for income taxes	\$ 171	\$ 2,673
Cash paid for interest	\$ 16,270	\$ 14,354
<b>Non-cash investing activities</b>		
Accounts payable and accrued liabilities incurred to acquire property and equipment	\$ 5,024	\$ 3,458
Assets obtained in exchange for lease obligations	\$ 5,028	\$ 27,443
Reductions to assets resulting from retirement of lease obligations	\$ (101)	\$ (66)

See notes to consolidated financial statements.

# Tata Chemicals North America Inc. and Subsidiaries

## Notes to Consolidated Financial Statements

### March 31, 2026 and 2025

---

*(in thousands)*

#### 1. Basis of Presentation

##### **Description of Business**

Tata Chemicals North America Inc. and subsidiaries, (“TCNA” or the “Company”) is a North American manufacturer and supplier of natural soda ash to a broad range of industrial and municipal customers. The primary end markets for soda ash include glass production, sodium-based chemicals, powdered detergents, water treatment, and other industrial end uses.

On March 27, 2008, TCNA was acquired by a subsidiary of Tata Chemicals Limited (“TCL”). The consolidated financial statements of TCNA are prepared on a historical cost basis and do not reflect the pushdown of the acquisition of TCNA by TCL.

Tata Chemicals Soda Ash Partners LLC (“TCSAP”) is a wholly-owned subsidiary of TCNA.

ALCAD is an equally-owned joint venture between TCSAP and Church & Dwight, Inc. (“C&D”) (collectively, the “Partners”).

For the purposes of these consolidated financial statements, fiscal 2026 is defined as the twelve-month year ended March 31, 2026 and fiscal 2025 is defined as the twelve-month year ended March 31, 2025.

#### 2. Summary of Significant Accounting Policies

##### **Basis of Presentation**

These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP).

##### **Principles of Consolidation**

The accompanying consolidated financial statements reflect the results of operations, financial position and cash flows of the Company, including wholly owned subsidiary, TCSAP. Intercompany balances and transactions are eliminated in consolidation. The portion of ALCAD that is not owned is reflected as noncontrolling interest in the accompanying consolidated financial statements.

The Company consolidates entities in which it has a controlling financial interest based on either the variable interest entity (VIE) or voting interest model. The Company is required to first apply the VIE model to determine whether it holds a variable interest in an entity, and if so, whether the entity is a VIE. If the Company determines it does not hold a variable interest in a VIE, it then applies the voting interest model. Under the voting interest model, the Company consolidates an entity when it holds a majority voting interest in an entity.

##### **Use of Estimates**

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include the useful lives of long-lived assets; allowance for credit losses; the valuation of deferred tax assets, derivatives, long-lived assets, inventory, goodwill, and lease liabilities and right-of-use assets; and reserve for pension and postretirement obligations, asset retirement obligation, and other contingencies. Actual results could differ from those estimates.

# Tata Chemicals North America Inc. and Subsidiaries

## Notes to Consolidated Financial Statements

### March 31, 2026 and 2025

---

*(in thousands)*

#### **Trade Accounts Receivables**

Accounts receivable are recorded at the invoiced amount and do not bear interest. Management periodically reviews customers' credit history and extends credit accordingly.

#### **Allowance for Credit Losses**

On April 1, 2023, the Company adopted the Current Expected Credit Losses (CECL) accounting standard under Topic 326 of the FASB Accounting Standards Codification. CECL requires estimated credit losses to be determined based on forward-looking methodology which incorporates the entire life of the asset. The Company records an allowance for credit losses based on historical experience, adjusted for current and reasonable and supportable forecasts of economic conditions and other pertinent factors affecting the Company's customers such as when it becomes aware of a specific customer's inability or unwillingness to meet its financial obligations. The Company estimates expected credit losses separately for domestic and foreign customers.

#### **Income Taxes**

The Company recognizes income taxes using the separate return method for the amount of taxes payable for the current year and deferred tax assets and liabilities for the future tax consequence of events that have been recognized differently in the consolidated financial statements than for tax purposes. Deferred tax assets and liabilities are established using statutory tax rates expected to apply when differences are expected to be settled or realized and are adjusted for tax rate changes. Deferred tax assets are valued at the amount that is more likely than not to be realized.

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records estimated interest and penalties related to unrecognized tax benefits, if any, as a component of the income tax provision.

#### **Inventories**

Inventories are stated at the lower of cost or net realizable value, with cost being determined using the average cost method. Product inventory costs include depreciation, maintenance, labor, energy, material and factory overhead.

#### **Property, Plant and Equipment**

The property, plant and equipment are carried at cost less accumulated depreciation. Plant and equipment under finance leases are stated at the present value of the lease payments less accumulated depreciation. Most property, plant and equipment are depreciated using the straight-line method, using estimated lives which range from 2 to 50 years. The mineral leases are depreciated using the units-of-production method. Leasehold improvements are amortized over the lesser of the useful life of the asset or term of the lease. Major additions and improvements are capitalized, while costs for minor replacements, maintenance and repairs that do not increase the functionality or useful life of an asset are expensed as incurred. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from the respective accounts and any resulting gain or loss is recorded.

# Tata Chemicals North America Inc. and Subsidiaries

## Notes to Consolidated Financial Statements

### March 31, 2026 and 2025

---

(in thousands)

#### Property, Plant, and Equipment useful lives

Land and improvements	5 to 30 years
Buildings and leasehold improvements	3 to 30 years
Machinery & Equipment	2 to 20 years
Mines & quarries	10 to 50 years
Machinery & Equipment - Leased	Set by lease agreement
Buildings - Leased	Set by lease agreement

#### Impairment of Long-Lived Assets

Long-lived assets, such as property, plant, and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. The Company measures the recoverability of these assets by comparing the carrying amount of such asset or asset group to the future undiscounted cash flows it expects the asset or asset group to generate over the remaining useful life of the primary asset. If the carrying amount of the long-lived asset or asset group is not recoverable, an impairment is recognized in the event that the carrying amount of the long-lived assets exceeds the fair value. There were no events or changes in circumstances that indicated long-lived assets were impaired during the years ended March 31, 2026 and 2025.

#### Goodwill

Goodwill represents the excess purchase price over the estimated fair value of net assets acquired in a business combination. Goodwill is not amortized into results of operations, but instead is reviewed for impairment. The Company records impairment losses on goodwill based upon the occurrence of a triggering event, or an annual review of the value of the assets or when events and circumstances indicate that the asset might be impaired and when the carrying value of the asset is more than its fair value. The goodwill impairment test begins with a qualitative analysis of factors that could be indicators of potential impairment. Next, if a quantitative analysis is necessary, the fair value of the reporting unit is compared with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, the goodwill of the reporting unit is not considered impaired. If the carrying amount of the reporting unit exceeds its fair value, an impairment charge is recognized for the amount by which the carrying amount exceeds the reporting unit's fair value.

Price pressure in the soda ash export market has eroded margins in those markets. This has led to declining financial performance for the Company. We used a combination of methods for determining whether an impairment of goodwill existed for the year ended March 31, 2026 – the market approach (based on the market capitalization of TCL at March 31, 2026) and the discounted cash flows method. We determined that an impairment of goodwill had occurred. An impairment of goodwill of \$225,000 and \$0 was recorded for the years ending March 31, 2026 and 2025, respectively.

#### Deferred Financing Costs

Deferred financing costs associated with the issuance of debt are offset against long-term debt and are amortized over the terms of the related debt. The amortization of deferred financing costs is charged to interest expense.

# Tata Chemicals North America Inc. and Subsidiaries

## Notes to Consolidated Financial Statements

### March 31, 2026 and 2025

---

*(in thousands)*

#### **Asset Retirement Obligations**

The Company provides for the expected costs to be incurred for the eventual reclamation of properties pursuant to local laws. The Company accounts for its land reclamation liability as an asset retirement obligation, which requires that obligations associated with the retirement of a tangible long-lived asset be recorded as a liability when those obligations are incurred, with the amount of the liability initially measured at fair value. Upon initially recognizing a liability for an asset retirement obligation, the Company must capitalize the cost by recognizing an increase in the carrying amount of the related long-lived asset. Over time, the liability is accreted to its future value each period, and the capitalized costs of the related long-lived assets are depreciated over their estimated useful lives. The Company ultimately either settles the obligation for its recorded amount or incurs a gain or loss upon settlement.

#### **Royalties**

Trona reserves are mined pursuant to lease arrangements with various landowners. Such arrangements generally provide for royalty or severance tax payments based on the selling price of soda ash. Royalties and severance taxes are included as a component of cost of revenues.

#### **Cash and Cash Equivalents**

The Company's cash and cash equivalents include cash and short-term highly liquid investments with an original maturity of three months or less. The Company maintains cash and cash equivalents in bank deposit and money market accounts that may exceed federally insured limits. The financial institutions where the Company's cash and cash equivalents are held are generally highly rated. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk.

#### **Derivative Financial Instruments**

Derivative financial instruments are used to mitigate natural gas purchase price and interest rates. The Company records all derivatives on the balance sheet at fair value. The Company's natural gas forwards are designated as fair value hedges and the interest rate swap are designated as cash flow hedges. Gains and losses on hedges are initially deferred in accumulated other comprehensive (loss) income, net of income taxes. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the earnings effect of the hedged forecasted transactions. Hedges are tested for effectiveness at inception of the hedge as well as in subsequent periods. If it is determined that hedging instruments are no longer effective at offsetting changes in the underlying hedged item, then the changes in fair value of the derivative instrument would be recorded immediately in the consolidated statements of income in the same caption as the hedged item. The Company does not hold or issue derivative instruments for trading purposes.

#### **Revenue Recognition**

The Company derives its revenues from the mining, processing, and sale of soda ash products. Revenues are recognized when the Company satisfies the performance obligation, under the terms of its contracts with customers, to transfer products to customers, which typically occurs at a point in time upon shipment of the products, and for an amount that reflects the transaction price that is allocated to the performance obligation.

The Company has applied the shipping and handling practical expedient to treat all shipping and handling activities as fulfillment activities as the Company views these costs as costs to fulfill the customers' orders. Fees for shipping and handling charged to customers for sales transactions are included in Net revenues on the consolidated statements of income. When control over products has

# Tata Chemicals North America Inc. and Subsidiaries

## Notes to Consolidated Financial Statements

### March 31, 2026 and 2025

---

*(in thousands)*

transferred to the customer, the Company has elected to recognize costs related to shipping and handling as an expense.

The Company's payment terms vary by the type of customer and the products offered. The term between invoicing and due date is not significant.

Unit price is determined at the time of the purchase order and is generally established on a customer-by-customer basis annually.

#### **Employee Medical Benefits**

The Company is self-insured for expenses relating to employee medical benefits. All employees have an option to participate in the Company's self-funded comprehensive medical care benefits program. The cost of medical care is paid out of employee and employer contributions. The Company has purchased stop-loss coverage in order to limit its exposure to any significant individual medical claims. Self-insured medical costs are accrued based upon actuarial assumptions and the Company's historical experience.

#### **Environmental Matters**

The Company is subject to extensive federal, state, and local environmental laws and regulations. These laws, which change frequently, regulate or propose to regulate the discharge of materials into the environment and may require the Company to remove or mitigate the environmental effects of the disposal or release of such substances. Environmental expenditures, which can include fines, penalties and certain corrective actions, are expensed or capitalized depending on their future economic benefit. Expenditures that relate to an existing condition caused by past operations and that have no future economic benefits are expensed. Liabilities for expenditures are recorded when environmental assessment and/or remediation is probable, and the costs can be reasonably estimated.

#### **Non-controlling Interest**

The Company accounts for non-controlling interests as a component of equity in the consolidated financial statements.

#### **Leases**

The Company determines if an arrangement is, or contains, a lease at contract inception based on whether there is an identified asset and whether the Company has the right to control the use of the identified asset throughout the period of use. The Company recognizes a right-of-use (ROU) asset and a lease liability at the lease commencement date. For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. For finance leases, the lease liability is initially measured in the same manner and date as for operating leases and is subsequently measured at amortized cost using the effective-interest method.

Key estimates and judgments include how the Company determines (1) the discount rate it uses to discount the unpaid lease payments to present value, (2) lease term, and (3) lease payments. The Company discounts its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. Generally, the Company cannot determine the interest rate implicit in the lease because it does not have access to the lessor's estimated residual value or the amount of the lessor's deferred initial direct costs. Therefore, the Company generally uses its incremental borrowing rate as the discount rate for the lease. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Because

# Tata Chemicals North America Inc. and Subsidiaries

## Notes to Consolidated Financial Statements

### March 31, 2026 and 2025

---

*(in thousands)*

the Company does not generally borrow on a collateralized basis, it uses the interest rate it pays on its noncollateralized borrowings as an input to deriving an appropriate incremental borrowing rate, the lease term and the effect on that rate of designating specific collateral with a value equal to the unpaid lease payments for that lease.

The lease term for all of the Company's leases includes the noncancelable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.

Lease payments included in the measurement of the lease liability comprise of the following:

- Fixed payments, including in-substance fixed payments, owed over the lease term (which includes termination penalties the Company would owe if the Company exercised the lease termination option);
- Variable lease payments that depend on an index or rate, initially measured using the index or rate at the lease commencement date;
- Amounts expected to be payable under a Company-provided residual value guarantee; and
- The exercise price of a Company option to purchase the underlying asset if the Company is reasonably certain to exercise the option.

The right of use (ROU) asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received.

For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense is recognized on a straight-line basis over the lease term.

For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability.

Variable lease payments associated with the Company's leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense in the Company's consolidated statements of operations in the same line item as expense arising from fixed lease payments (operating leases) or amortization of the ROU asset (finance leases).

ROU assets for operating and finance leases are periodically reduced by impairment losses and the Company evaluates the ROU asset for impairment loss using the same methodology as for long-lived assets.

The Company monitors for events or changes in circumstances that require a reassessment of one of its leases. When a reassessment results in the remeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the corresponding ROU asset unless doing so would

# Tata Chemicals North America Inc. and Subsidiaries

## Notes to Consolidated Financial Statements

### March 31, 2026 and 2025

---

(in thousands)

reduce the carrying amount of the ROU asset to an amount less than zero. In that case, the amount of the adjustment that would result in a negative ROU asset balance is recorded in profit or loss.

Finance lease ROU assets are included in property, plant, and equipment. The current portion of finance lease liabilities is included in current portion of finance lease obligation and the long-term portion is included in finance lease obligation, net of current portion in the consolidated balance sheet.

The Company has elected not to recognize ROU assets and lease liabilities for short-term leases of equipment that have a lease term of 12 months or less. The Company recognizes the lease payments associated with its short-term equipment leases as an expense on the consolidated statements of operations. Variable lease payments associated with these leases are recognized and presented in the same manner as for all other Company leases.

The Company has lease agreements with lease and non-lease components and has elected a practical expedient not to separate the lease and non-lease components for its leases for physical space and equipment and accounts for them as a single lease component.

#### **Accounting Pronouncements Not Yet Adopted**

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which requires, among other things, enhanced annual disclosures for domestic and foreign income taxes paid. ASU 2023-09 is effective for private companies for annual reporting periods beginning after December 15, 2025. We are currently evaluating the impact that adopting this new accounting standard will have on our disclosures.

### **3. Fair Value Measurements**

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in a principal or most advantageous market. The Company makes certain assumptions it believes that market participants would use in pricing assets or liabilities, including assumptions about risk, and the risks inherent in the inputs to valuation techniques. The credit risk of the Company and its counterparties is incorporated in the valuation of assets and liabilities using credit reserves, the impact of which is immaterial for the years ended March 31, 2026 and 2025. The Company believes it uses valuation techniques that maximize the use of observable market-based inputs and minimize the use of unobservable inputs.

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. These tiers include:

- Level 1, defined as quoted market prices in active markets for identical assets or liabilities;
- Level 2, defined as inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, model-based valuation techniques for which all significant assumptions are observable in the market, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
- Level 3, defined as unobservable inputs that are not corroborated by market data.

**Tata Chemicals North America Inc. and Subsidiaries**  
**Notes to Consolidated Financial Statements**  
**March 31, 2026 and 2025**

---

(in thousands)

The following table presents the fair values for those assets and liabilities measured on a recurring basis as of March 31, 2026:

	<b>Fair Value Measurements</b>		
	<b><u>Level 1</u></b>	<b><u>Level 2</u></b>	<b><u>Total</u></b>
<b>Assets:</b>			
Cash equivalents	\$ 9,812	\$ -	\$ 9,812
Non-qualified pension asset	<u>2,006</u>	<u>-</u>	<u>2,006</u>
	<u>\$ 11,818</u>	<u>\$ -</u>	<u>\$ 11,818</u>
<b>Liabilities:</b>			
Natural gas futures contracts	\$ -	\$ (5,544)	\$ (5,544)

The following table presents the fair values for those assets and liabilities measured on a recurring basis as of March 31, 2025:

	<b>Fair Value Measurements</b>		
	<b><u>Level 1</u></b>	<b><u>Level 2</u></b>	<b><u>Total</u></b>
<b>Assets:</b>			
Cash equivalents	\$ 40,251	\$ -	\$ 40,251
Non-qualified pension asset	<u>1,895</u>	<u>-</u>	<u>1,895</u>
	<u>\$ 42,146</u>	<u>\$ -</u>	<u>\$ 42,146</u>
<b>Liabilities:</b>			
Natural gas futures contracts	\$ -	\$ (1,906)	\$ (1,906)

**Cash Equivalents and Non-Qualified Pension Assets**

The cash equivalents shown in the fair value table are comprised of money market funds. Non-qualified pension assets include investments in listed equity securities. The fair values of the shares of these funds are based on observable market prices and, therefore, have been categorized as Level 1 in the fair value hierarchy.

**Commodity Futures Contracts**

The inputs used in valuing natural gas contracts are based on a regional basis forward price quoted by a third-party service.

**Tata Chemicals North America Inc. and Subsidiaries**  
**Notes to Consolidated Financial Statements**  
**March 31, 2026 and 2025**

(in thousands)

**4. Property, Plant and Equipment, net**

Property, plant and equipment, net as of March 31, 2026 and 2025 are comprised of the following:

	<u>2026</u>	<u>2025</u>
Land and improvements	\$ 109,805	\$ 79,323
Buildings and leasehold improvements	95,543	94,619
Machinery and equipment	562,603	537,812
Construction-in-progress	32,845	52,203
Mines and quarries	<u>28,627</u>	<u>28,627</u>
Total gross owned assets	829,423	792,584
Less: Accumulated depreciation	<u>534,899</u>	<u>502,372</u>
Total net owned assets	<u>294,524</u>	<u>290,212</u>
Leased - Equipment	\$ 63,715	\$ 59,488
Leased - Buildings	<u>4,199</u>	<u>4,095</u>
Total gross leased assets	67,914	63,583
Less: Accumulated depreciation	<u>32,797</u>	<u>22,284</u>
Total net leased assets	<u>35,117</u>	<u>41,299</u>
Total net assets	<u>\$ 329,641</u>	<u>\$ 331,511</u>

For the years ended March 31, 2026 and 2025, the Company recognized \$33,026 and \$30,018 of depreciation expense relating to owned assets, respectively. For the years ended March 31, 2026 and 2025, the Company recognized \$11,112 and \$11,009 of depreciation expense relating to leased assets, respectively.

**5. Accumulated Other Comprehensive Income (Loss)**

The following table sets forth the components of accumulated other comprehensive loss as of March 31, 2026 and 2025:

	<u>2026</u>	<u>2025</u>
Pension and post retirement plan benefits, net of taxes	\$ 24,830	\$ 15,320
Natural gas hedges, net of taxes	<u>(4,186)</u>	<u>(1,161)</u>
Total accumulated other comprehensive income	<u>\$ 20,644</u>	<u>\$ 14,159</u>

# Tata Chemicals North America Inc. and Subsidiaries

## Notes to Consolidated Financial Statements

### March 31, 2026 and 2025

---

(in thousands)

#### 6. Receivables Purchase Agreement

On March 30, 2023, the Company entered into a Receivables Purchase agreement (the "Purchase Agreement") with Citibank, N.A. Singapore Branch (the "Purchaser"). Per the terms of the Purchase Agreement, the Company may sell certain indebtedness and related payment obligations owed to the Company, to the Purchaser with limited recourse of up to 5% of the indebtedness in the event of debtor insolvency, in exchange for cash. At any given time, the Company may sell up to \$25.35M in customer indebtedness, with limits established on a per debtor basis. As debtors make payments on the indebtedness sold to the Purchaser, the Company may sell additional indebtedness to the Purchaser up to the established limits. The Purchase Agreement renews automatically on an annual basis unless terminated by either party.

Transactions under the Purchase Agreement are accounted for as sales under *ASC 860, Transfers and Servicing of Financial Assets*, with the sold receivables removed from the Company's balance sheet. Under the Purchase Agreement, the Company does not maintain any beneficial interest in the receivables sold. The Company performs limited administrative services on behalf of the Purchaser, but otherwise maintains no significant continuing involvement with respect to the receivables. Sales proceeds that are representative of the fair value of factored receivables, less a factoring fee of Term SOFR +1.45%, with a floor of 1.45%, are reflected in cash flows from operating activities on the consolidated statements of cash flows.

During the years ended March 31, 2026 and 2025, the Company received cash proceeds of \$39,316 and \$94,723, respectively, from the sales of accounts receivable under the Purchase Agreement. The Company's loss on these transactions, the cost of factoring such receivables, is reflected in Selling, general and administrative expense on the consolidated statements of operations and was \$490 and \$1,381 for the year ended March 31, 2026 and 2025, respectively.

**Tata Chemicals North America Inc. and Subsidiaries**  
**Notes to Consolidated Financial Statements**  
**March 31, 2026 and 2025**

---

(in thousands)

**7. Additional Financial Information**

The summaries of selected balance sheet items as of March 31, 2026 and 2025 are as follows:

	<b>2026</b>	<b>2025</b>
<b>Receivables</b>		
Trade	\$ 108,717	\$ 97,972
Other	4,925	4,619
Allowance for credit losses	<u>(895)</u>	<u>(895)</u>
	<u>\$ 112,747</u>	<u>\$ 101,696</u>
<b>Allowance for credit losses</b>		
Balance at April 1	\$ (895)	\$ (895)
Write-offs	-	-
Recoveries	-	-
Allowance for credit losses	<u>-</u>	<u>-</u>
Balance at March 31	<u>\$ (895)</u>	<u>\$ (895)</u>
<b>Inventories</b>		
Raw materials	\$ 18,466	\$ 20,164
Work-in-process	100	100
Finished products	<u>17,395</u>	<u>16,141</u>
	<u>\$ 35,961</u>	<u>\$ 36,405</u>
<b>Other Assets</b>		
Non-qualified pension asset	\$ 2,006	\$ 1,895
Spare parts	23,647	21,118
Long-term deposit	<u>148</u>	<u>184</u>
	<u>\$ 25,801</u>	<u>\$ 23,197</u>
<b>Accrued Liabilities</b>		
Wages, salaries, and benefits	\$ 13,926	\$ 14,185
Property, production and other taxes	6,363	4,815
Unrealized loss for natural gas futures	5,544	1,906
Other	<u>6,721</u>	<u>7,287</u>
	<u>\$ 32,554</u>	<u>\$ 28,193</u>
<b>Other Liabilities</b>		
Accrued pension obligations	\$ 12,558	\$ 29,776
Accrued other post-retirement benefits	8,930	9,242
Asset retirement obligation	34,782	33,105
Accrued other	<u>6,478</u>	<u>8,835</u>
	<u>\$ 62,748</u>	<u>\$ 80,958</u>

# Tata Chemicals North America Inc. and Subsidiaries

## Notes to Consolidated Financial Statements

### March 31, 2026 and 2025

---

(in thousands)

#### 8. Debt

On December 17, 2021, the Company entered into a credit agreement with several lenders led by Bank of America, N.A. ("BoA"), as administrative agent. The credit agreement provided for a \$100,000 credit facility, composed of a \$100,000 term loan ("BoA loan") with a 5-year term. The borrowing under this facility bears interest at SOFR plus a Term SOFR Adjustment of between 0.11448% and 0.71513% depending on the interest period selected, plus applicable margin. The BoA loan effective rate as of March 31, 2026 and 2025 was 5.18 and 5.96%, respectively. The applicable margin on the BoA loan was 1.4% per annum on SOFR borrowings in 2026 and in 2025.

On May 8, 2026, the Company entered into a credit agreement with several lenders led by BoA as administrative agent. The credit agreement provided for a \$150,000 term loan ("New BoA loan"). The New BoA Loan is expected to mature on May 8, 2030. The borrowing under this facility bears interest at SOFR plus applicable margin of 1.15%. This was approximately 4.79% at the closing date of May 8, 2026. The New BoA loan is a refinancing of the BoA loan. As such, the BoA loan was paid in full on May 8, 2026.

The BoA loan is secured by 25% of the ownership interest in TCSAP held by the Company. The BoA loan is subject to certain covenants, including, but not limited to the Company maintaining a net worth of not less than \$0. Additionally, TCL is subject to certain covenants under the BoA loan, including, but not limited to maintaining a Total Net Debt to Net Worth ratio of greater than 1.75, a Net Debt to EBITDA ratio of under 4.5, and an EBITDA to Net Finance Charges ratio of over 2.5.

On March 27, 2025, the Company entered into a credit agreement with Australia and New Zealand Banking Group Limited ("ANZ"). The credit agreement provided for a \$95,000 credit facility, composed of a \$95,000 term loan ("ANZ loan") with a 3-year term. The borrowing under this facility bears interest at Daily Compounded SOFR plus the applicable margin of 1.0%. The ANZ loan effective rate as of March 31, 2026 and 2025 was 4.63% and 5.3%, respectively. The ANZ loan matures on March 27, 2028.

The ANZ loan is unsecured, backed by a Letter of Comfort issued by TCL. The ANZ loan is subject to certain covenants, including, but not limited to the Company maintaining a net worth of not less than \$0. Additionally, TCL is subject to certain covenants under the ANZ loan, including, but not limited to maintaining a Total Net Debt to Net Worth ratio of greater than 1.75, a Net Debt to EBITDA ratio of under 4.5, and an EBITDA to Net Finance Charges ratio of over 2.5.

The Company was in compliance with all covenants related to the loans mentioned above as of March 31, 2026.

#### Revolving Credit Facility

On November 30, 2022, the Company entered into an uncommitted line of credit with Bank of America, N.A. (the "RCF Agreement"), in an amount not to exceed, in the aggregate, at any one time, \$25,000, subsequently increased to \$50,000 via an amendment dated December 16, 2024. The RCF Agreement allows for individual draws against the facility at a rate per annum equal to Term SOFR plus applicable margin of 1.25% for terms ranging from one to three months. Any individual draw against the facility may be rolled over perpetually for an additional one to three months at the updated interest rate, through the termination date of the RCF Agreement. The RCF Agreement matures November 30, 2027 unless terminated earlier by either party or extended by agreement of both parties. As of March 31, 2026 and March 31, 2025, the Company had \$50,000 and \$49,000, respectively, outstanding under the revolving credit facility.

**Tata Chemicals North America Inc. and Subsidiaries**  
**Notes to Consolidated Financial Statements**  
**March 31, 2026 and 2025**

---

(in thousands)

**AP Finance**

On June 4, 2025, the Company entered into trade loan facility agreement with Citibank (the "Agreement"). The Agreement allows the Company to draw, or request, funds up to \$50,000 total from Citibank to pay vendor invoices. Repayment to Citibank is on 90-day terms for each request. The annual interest rate for each request is SOFR plus a 1.4% margin. As of March 31, 2026, requests totaling \$31,808 were outstanding with the last request made on March 31, 2026 which matures on June 29, 2026.

The debt balance is as follows as of March 31:

	<u>2026</u>	<u>2025</u>
BoA loan - SOFR plus 1.4%;	\$ 100,000	\$ 100,000
ANZ loan - SOFR plus 1.0%	95,000	95,000
Revolving credit facility - SOFR plus 1.25%;	50,000	49,000
AP Financing - SOFR plus 1.4%;	31,808	-
Unamortized debt issuance costs	<u>(568)</u>	<u>(955)</u>
 Total debt	 276,240	 243,045
Current Portion	<u>(81,808)</u>	<u>(49,000)</u>
 Long-term debt, net of current portion	 <u>\$ 194,432</u>	 <u>\$ 194,045</u>

Amortization of the deferred finance fees for the years ending March 31, 2026 and March 31, 2025, was \$387 and \$1,542, respectively.

Debt maturities for fiscal years subsequent to March 31, 2026 are as follows:

**Years ending March 31,**

2027	\$ 81,808
2028	95,000
2029	-
2030	<u>100,000</u>
	<u>\$ 276,808</u>

**Tata Chemicals North America Inc. and Subsidiaries**  
**Notes to Consolidated Financial Statements**  
**March 31, 2026 and 2025**

---

(in thousands)

**9. Income Taxes**

Income tax expense (benefit) for the years ended March 31, 2026 and 2025 is summarized below:

	<u>2026</u>	<u>2025</u>
<b>Current</b>		
Federal	\$ 804	\$ 971
State	<u>364</u>	<u>300</u>
Total current	<u>1,168</u>	<u>1,271</u>
<b>Deferred</b>		
Federal	13,058	(1,787)
State	<u>(614)</u>	<u>(30)</u>
Total deferred	<u>12,444</u>	<u>(1,817)</u>
Total	<u>\$ 13,612</u>	<u>\$ (546)</u>

A summary of the components of deferred tax assets and liabilities is as follows:

	<u>2026</u>	<u>2025</u>
Pension and post retirement benefits	\$ 4,517	\$ 7,757
Nondeductible accruals	7,824	5,628
Lease liabilities	8,199	9,438
Other	8,513	7,902
Net operating Loss	<u>9,178</u>	<u>1,038</u>
Deferred tax assets	38,231	31,763
Valuation allowance	<u>20,586</u>	<u>-</u>
Net deferred tax assets	<u>17,645</u>	<u>31,763</u>
Depreciation	14,687	13,700
Right of use assets	<u>7,600</u>	<u>8,954</u>
Deferred tax liabilities	<u>22,287</u>	<u>22,654</u>
Net deferred tax (liability) asset	<u>\$ (4,642)</u>	<u>\$ 9,109</u>

# Tata Chemicals North America Inc. and Subsidiaries

## Notes to Consolidated Financial Statements

### March 31, 2026 and 2025

---

*(in thousands)*

The Company's effective income tax rate was lower than the statutory Federal income tax rate principally due to goodwill impairment and the change in the valuation allowance for the year ended March 31, 2026 and principally due to mineral depletion for the year ended March 31, 2025.

The Company has assessed the realizability of the net deferred tax assets as of March 31, 2026 and in that analysis has considered the relevant positive and negative evidence available to determine whether it is more likely than not that some portion or all of the deferred income tax assets will be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income through the reversal of existing deferred tax liabilities and projected taxable income. The Company believes that it is more likely than not that there will not be sufficient income in the future to realize the Company's deferred tax assets. Therefore, a valuation allowance was posted as of March 31, 2026.

The Company has determined that there is no tax liability resulting from unrecognized tax benefits from uncertain tax positions taken or expected to be taken on a return for the years ended March 31, 2026 and prior. The Company's federal and state tax returns remain open and are subject to future examination by the taxing authorities in those jurisdictions. Open tax periods subject to examination by the taxing authorities include the fiscal year ended March 31, 2022 and forward for all tax returns.

#### **Impact of the One Big Beautiful Bill Act**

In July 2025, the One Big Beautiful Bill Act ("OBBBA") was enacted into law, introducing significant changes to U.S. federal taxation. The OBBBA impacts the timing of recognition of certain expenses, including depreciation, research and experimentation costs and interest, which impacts taxable income. The Company evaluated the impact of the OBBBA as of the enactment date in accordance with applicable tax and accounting guidance and has included the results in its income tax provision for the period ended March 31, 2026. Additionally, the Company continues to evaluate the OBBBA, including reviewing forthcoming regulatory guidance and interpretations and will consider such evaluation in its income tax provisions for periods ended post March 31, 2026.

#### **10. Commodity Futures Contracts and Interest Rate Swaps**

The Company enters into commodity futures contracts related to forecasted natural gas requirements that are used in the manufacturing process of its products, the objectives of which are to secure supply and limit the effects of fluctuations in the future market price paid for natural gas and in the related volatility in cash flows. The maturities of the contracts are timed to coincide with the expected usage of the gas.

The Company meets the requirements to account for its natural gas hedges under hedge accounting. For the years ending March 31, 2026 and 2025, the Company recorded an unrealized loss of \$(3,638) and unrealized gain of \$9,221, respectively, in the consolidated statements of comprehensive income. The balances associated with the commodity futures contracts of \$5,544 and \$1,906 are included in accrued liabilities in the consolidated balance sheets as of March 31, 2026 and 2025 respectively. As of March 31, 2026, the notional amounts of the natural gas futures are \$18,254 expiring in March 2027.

The Company enters into interest rate swaps to manage its exposure to interest rate variations on its floating-rate borrowings. The objective is to reduce its exposure to variability attributable to changes in the 3-month SOFR rate underlying its SOFR-indexed floating-rate debt (See Note 8). The Company entered into an interest rate swap effective October 6, 2022 with notional amount of \$75,000. The swap has a fixed rate of 3.32% and floating rate of 3-month SOFR. The swap

# Tata Chemicals North America Inc. and Subsidiaries

## Notes to Consolidated Financial Statements

### March 31, 2026 and 2025

---

*(in thousands)*

terminated October 7, 2024. The swap qualifies for hedge accounting, and unrealized gains or losses are included as adjustments to other comprehensive income.

For the years ended March 31, 2026 and 2025, the Company reported unrealized losses of \$0 and \$(1,081), respectively, in the consolidated statements of comprehensive income.

#### **11. Pension Plans and Other Postretirement Benefits**

The Company maintains several defined benefit pension plans covering substantially all employees hired prior to February 1, 2017. Salaried defined benefit plans were frozen to new entrants effective September 6, 2016 and hourly defined benefit plans were frozen to new entrants effective July 1, 2017. A participating employee's annual postretirement pension benefit is determined by the employee's credited service and, in most plans, final average annual earnings with the Company. Vesting requirements are two years. The Company's funding policy is to annually contribute the statutorily required minimum amount as actuarially determined. The Company also maintains several plans providing other postretirement benefits covering substantially all hourly and certain salaried employees hired prior to July 1, 2017 and February 1, 2017, respectively, these plans also not being available to new entrants after these dates. The Company recognizes actuarially determined liabilities for these benefits, but funds these benefits on a pay-as-you-go basis. The accumulated benefit obligation for all defined benefit plans was \$166,877 and \$170,301 as of March 31, 2026 and 2025, respectively.

The Company recorded adjustments to other comprehensive income (loss) of \$9,510 and \$(1,899), net of tax of \$(1,921) and \$531, for the years ended March 31, 2026 and 2025, respectively. The Company's operating pension expenses are included in cost of revenues and the non-operating pension expenses are included in other expense, net.

The components of net periodic benefit cost, change in benefit obligation, change in plan assets, and reconciliation of the funded status as of and for the years ended March 31, 2026 and 2025 are summarized in the table below.

**Tata Chemicals North America Inc. and Subsidiaries**  
**Notes to Consolidated Financial Statements**  
**March 31, 2026 and 2025**

(in thousands)

	Pension Benefits		Other Postretirement Benefits	
	2026	2025	2026	2025
<b>Components of net periodic benefit cost</b>				
Service cost	\$ 3,278	\$ 3,350	\$ 82	\$ 90
Operating expense	3,278	3,350	82	90
Interest cost	9,542	9,375	535	529
Expected return on plan assets	(10,603)	(9,712)	-	-
Amortization of unrecognized:				
Prior service cost (gain)	63	63	(972)	(972)
Actuarial loss (gain)	(183)	(173)	(370)	(376)
Settlement/Curtailment Expense	-	-	-	-
Non-operating income	(1,181)	(447)	(807)	(819)
Net periodic benefit cost (income)	\$ 2,097	\$ 2,903	\$ (725)	\$ (729)
<b>Change in benefit obligation</b>				
Benefit obligation - beginning of year	\$ 178,990	\$ 177,333	\$ 9,948	\$ 10,542
Service cost	3,278	3,350	82	90
Interest cost	9,542	9,375	535	529
Plan amendments	-	-	-	-
Actuarial (gain)	(7,673)	(507)	(285)	(558)
Benefits paid	(10,581)	(10,561)	(632)	(655)
Annuity liftout payments	-	-	-	-
Liability (gain) due to mid-year remeasurement	-	-	-	-
Projected Benefit obligation - end of year	\$ 173,556	\$ 178,990	\$ 9,648	\$ 9,948
<b>Change in plan assets</b>				
Fair value of assets - beginning of year	\$ 148,937	\$ 144,353	\$ -	\$ -
Actual return on plan assets	15,539	7,674	-	-
Employer contributions	6,826	7,471	632	655
Annuity Liftout Payments	-	-	-	-
Benefits paid	(10,581)	(10,561)	(632)	(655)
Fair value of assets - end of year	\$ 160,721	\$ 148,937	\$ -	\$ -
<b>Reconciliation of funded status</b>				
Funded status	\$ (12,835)	\$ (30,053)	\$ (9,648)	\$ (9,948)
Net amount accrued	\$ (12,835)	\$ (30,053)	\$ (9,648)	\$ (9,948)
Net amount accrued in current liabilities	(277)	(277)	(718)	(706)
Net amount accrued in other liabilities	(12,558)	(29,776)	(8,930)	(9,242)

**Tata Chemicals North America Inc. and Subsidiaries**  
**Notes to Consolidated Financial Statements**  
**March 31, 2026 and 2025**

(in thousands)

The amounts recognized in accumulated other comprehensive loss as of March 31, 2026 and 2025, before accumulated tax, are summarized below:

	Pension Benefits		Other Postretirement Benefits	
	2026	2025	2026	2025
Prior service cost/(credit)	\$ 364	\$ 427	\$ (5,727)	\$ (6,700)
Net actuarial loss/(gain)	(3,096)	9,330	(5,878)	(5,963)
Total	<u>\$ (2,732)</u>	<u>\$ 9,757</u>	<u>\$ (11,605)</u>	<u>\$ (12,663)</u>

The amounts recognized in other comprehensive income during the years ended March 31, 2026 and 2025, before tax, are summarized below:

	Pension Benefits		Other Postretirement Benefits	
	2026	2025	2026	2025
Net actuarial loss (gain)	\$ (12,609)	\$ 1,531	\$ (284)	\$ (558)
Prior service cost	-	-	-	-
Reversal of amortization item:				
Prior service (cost)/credit	(63)	(63)	972	972
Net actuarial (loss) gain	183	173	370	376
Total recognized in comprehensive (income) loss	<u>\$ (12,489)</u>	<u>\$ 1,641</u>	<u>\$ 1,058</u>	<u>\$ 790</u>

**Assumptions**

The weighted-average assumptions used to determine net periodic benefit cost were as follows:

	Pension Benefits		Other Postretirement Benefits	
	2026	2025	2026	2025
Discount rate	5.55 %	5.38 %	5.54 %	5.37 %
Expected long-term return on plan assets	6.50 %	6.25 %	N/A	N/A
Rate of compensation increase	5.30–8.40%	5.30–8.40%	N/A	N/A

The weighted-average assumptions used to determine the benefit obligation were as follows:

	Pension Benefits		Other Postretirement Benefits	
	2026	2025	2026	2025
Discount rate	5.84 %	5.55 %	5.82 %	5.54 %
Rate of compensation increase	4.60–5.60%	5.30–8.40%	N/A	N/A

The discount rate for each plan is determined by discounting the plan's expected future benefit payments using a yield curve developed from high quality bonds as of the measurement date. The yield curve calculation matches the notional cash inflows or hypothetical bond portfolio with the expected benefit payments to arrive at an effective rate.

**Tata Chemicals North America Inc. and Subsidiaries**  
**Notes to Consolidated Financial Statements**  
**March 31, 2026 and 2025**

---

(in thousands)

To determine the expected long-term rate of return on plan assets, the Company considers the current and expected asset allocation, as well as historical and expected returns on each plan asset class.

The dates used to measure plan assets and liabilities were March 31, 2026 and 2025 for all plans.

For healthy lives, the Company measured benefit obligation using the amounts-weighted rates from the Pri-2012 mortality study with blue- and white-collar adjustments by individual, projected generationally from 2012 with Scale MP-2021 as of March 31, 2026.

For surviving beneficiaries, the Company measured benefit obligations using the amounts-weighted contingent survivor rates from the Pri-2012 mortality study with blue- and white-collar adjustments by individual, projected generationally from 2012 with Scale MP-2021 as of March 31, 2026.

For disabled lives, the Company measured benefit obligation using the amounts-weighted disabled retiree rates from the Pri-2012 mortality study, projected generationally from 2012 with Scale MP-2021 as of March 31, 2026.

**Plan Assets**

Pension plan assets are invested primarily in stocks, bonds, short-term securities and cash equivalents. The assets of the Company's defined benefit plans are managed on a commingled basis in a Master Trust. The investment policy and allocation of the assets in the Master Trust were approved by the Company's Investment Committee, which has oversight responsibility for the Company's retirement plans.

The following details the asset categories including target allocations for the pension plan as of March 31, 2026 and 2025:

Asset Category	2026		2025	
	Actual Allocation	Target Allocation	Actual Allocation	Target Allocation
Equity Securities	45 %	51 %	49 %	51 %
Debt Securities	50 %	45 %	46 %	45 %
Other	5 %	4 %	5 %	4 %

The pension fund assets are invested in accordance with the statement of Investment Policies and Procedures adopted by the Company, which are reviewed annually. Pension fund assets are invested on a going-concern basis with the primary objective of providing reasonable rates of return consistent with available market opportunities, a quality standard of investment, and moderate levels of risk. The expected rate of return is expected to be 6.50% over rolling ten-year periods. This expected rate of return is estimated upon an analysis of historical returns with consideration for the current economic environment.

**Contributions**

The Company expects to contribute \$8,603 to its pension plan and \$718 to its other postretirement benefit plans for the year ending March 31, 2027.

**Tata Chemicals North America Inc. and Subsidiaries**  
**Notes to Consolidated Financial Statements**  
**March 31, 2026 and 2025**

---

(in thousands)

**Estimated Future Benefit Payments**

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:

	<u>Pension Benefits</u>	<u>Other Benefits</u>
<b>Years ending March 31,</b>		
2027	\$ 13,044	\$ 718
2028	12,865	728
2029	13,146	728
2030	12,621	725
2031	12,617	720
2032-2036	66,278	3,575

**Fair Values**

The fair values of the Company's plan assets as of March 31, 2026, by asset category are as follows:

	<u>Level 1</u>	<u>Level 2</u>	<u>Total</u>
<b>Asset Category:</b>			
Cash and cash equivalents	\$ 227	\$ 1,681	\$ 1,908
Fixed income securities	19,454	60,798	80,252
Preferred securities	-	28	28
Equity securities	12,750	60,327	73,077
Futures contracts	(123)	-	(123)
Real estate investments trusts	-	5,579	5,579
Total	<u>\$ 32,308</u>	<u>\$ 128,413</u>	<u>\$ 160,721</u>

The fair values of the Company's plan assets as of March 31, 2025, by asset category are as follows:

	<u>Level 1</u>	<u>Level 2</u>	<u>Total</u>
<b>Asset Category:</b>			
Cash and cash equivalents	\$ 28	\$ 1,358	\$ 1,386
Fixed income securities	15,287	52,538	67,825
Preferred securities	-	28	28
Equity securities	12,322	61,217	73,539
Futures contracts	60	-	60
Real estate investments trusts	-	6,099	6,099
Total	<u>\$ 27,697</u>	<u>\$ 121,240</u>	<u>\$ 148,937</u>

**Tata Chemicals North America Inc. and Subsidiaries**  
**Notes to Consolidated Financial Statements**  
**March 31, 2026 and 2025**

---

(in thousands)

**Valuation**

Cash and cash equivalents are held in a commingled fund utilizing various underlying pricing sources.

Level one securities are valued using quoted prices in active markets for identical assets accessible to the company at the measurement date.

Level two fixed income securities are primarily valued using a market approach utilizing various underlying pricing sources and methodologies.

Level two equity securities and real estate investment trusts are valued using a market approach based on quoted market prices for similar instruments.

**Other Defined Contribution Plans**

The Company also sponsors defined contribution retirement savings plans. Participation in one of these plans is available to substantially all represented and non-represented employees. The Company matches employee contributions up to certain predefined limits for non-represented employees based upon eligible compensation and the employee's contribution rate. The Company's contribution to these plans was \$3,044 and \$2,865 for the years ended March 31, 2026 and 2025, respectively.

**12. Asset Retirement Obligation**

The Company provides for the expected costs to be incurred for the eventual reclamation of mining properties pursuant to local law. All estimates are determined by a third-party contractor who specializes in mine closure evaluations. Included in long-term liabilities as of March 31, 2026 and 2025 were \$34,782 and \$33,105, respectively, related to these asset retirement obligations. Changes in the carrying amounts of the asset retirement obligation were as follows:

	<b>2026</b>	<b>2025</b>
Balance - beginning of year	\$ 33,105	\$ 28,961
Change in estimate	-	-
Accretion expense	<u>1,677</u>	<u>4,144</u>
Balance - end of year	<u>\$ 34,782</u>	<u>\$ 33,105</u>

**13. Variable Interest Entity (VIE)**

The consolidated financial statements include a VIE, ALCAD, for which TCSAP is the primary beneficiary.

The significant activities of ALCAD include (a) managing trona reserves dedicated to it by the Partners, (b) extraction of trona for conversion into soda ash (which ALCAD has outsourced to TCSAP) and (c) distribution of soda ash exclusively to C&D. TCSAP was determined to be the primary beneficiary of ALCAD as it has control over all significant activities of ALCAD. TCSAP has the obligation to absorb losses and the right to receive benefits from ALCAD that could be significant to ALCAD.

**Tata Chemicals North America Inc. and Subsidiaries**  
**Notes to Consolidated Financial Statements**  
**March 31, 2026 and 2025**

---

(in thousands)

During the years ended March 31, 2026 and 2025, this VIE earned income of \$22,437 and \$22,604, respectively, under the contractual arrangements between the Partners, 50% of which was recorded as net income attributable to noncontrolling interests in the consolidated statements of income.

The liabilities recognized as a result of consolidating the VIE's do not necessarily represent additional claims on the general assets of the TCSAP outside of the VIE's; rather, they represent claims against the specific assets of the consolidated VIE. Conversely, assets recognized as a result of consolidating the VIE do not necessarily represent additional assets that could be used to satisfy claims against the TCSAP's general assets. There are no restrictions on the VIE's assets that are reported in the TCSAP's general assets.

The total accounts receivable of \$8,115 and \$7,145 are recorded in receivables as of March 31, 2026 and 2025. The liabilities not eliminated in consolidation of \$821 and \$794 are recorded in accrued liabilities as of March 31, 2026 and 2025.

**14. Related Party Transactions**

In the ordinary course of business, the Company purchases from, reimburses costs of, and sells soda ash to TCL and its subsidiaries. During the years ended March 31, 2026 and 2025, the purchases from and reimbursement of costs of TCL and subsidiaries amounted to \$987 and \$745, respectively; and accounts payable amounted to \$128 and \$247 at March 31, 2026 and 2025, respectively. During the years ended March 31, 2026 and 2025, the sales to TCL and its subsidiaries, amounted to \$22,400 and \$23,781, respectively, of which \$19,922 is still outstanding, included in Receivables on the balance sheet as of March 31, 2026.

**15. Leases**

The Company is obligated under finance leases that expire at various dates in the future.

The following table provides the lease costs for the years ended March 31, 2026 and 2025:

	<u>2026</u>	<u>2025</u>
Finance lease cost		
Amortization of leased assets	\$ 11,111	\$ 11,009
Interest on lease liabilities	<u>2,473</u>	<u>2,085</u>
Total finance lease cost	<u>\$ 13,584</u>	<u>\$ 13,094</u>
Expensed lease cost	<u>\$ 2,237</u>	<u>\$ 3,505</u>
Total lease cost	<u>\$ 15,821</u>	<u>\$ 16,599</u>

**Tata Chemicals North America Inc. and Subsidiaries**  
**Notes to Consolidated Financial Statements**  
**March 31, 2026 and 2025**

---

(in thousands)

Short-term lease cost and variable lease cost is not material to the financial statements as of March 31, 2026 and 2025. Amounts reported in the consolidated balance sheet as of March 31, 2026 and 2025 were as follows:

	<u>2026</u>	<u>2025</u>
Finance leases		
Leased assets	\$ 67,913	\$ 63,584
Accumulated amortization	<u>(32,797)</u>	<u>(22,284)</u>
Property, plant and equipment, net	<u>\$ 35,116</u>	<u>\$ 41,300</u>
Current portion of lease liabilities	\$ 10,829	\$ 10,013
Long-term portion of lease liabilities	<u>27,312</u>	<u>33,748</u>
Total finance lease liabilities	<u>\$ 38,141</u>	<u>\$ 43,761</u>

Other information related to leases as of March 31, 2026 and 2025 was as follows:

Weighted average incremental borrowing rates for the finance leases was 5.98% and 5.92%, for March 31, 2026 and 2025, respectively. Weighted average remaining lease term for the finance leases is approximately 36 months and 43 months, for March 31, 2026 and 2025, respectively.

Future minimum rental payments for leases (primarily for transportation equipment, mining equipment, offices and warehouses) as of March 31, 2026 are as follows:

	<u>Finance Leases</u>
<b>Years ending March 31,</b>	
2027	\$ 12,979
2028	12,660
2029	9,033
2030	4,830
2031	967
Thereafter	<u>2,240</u>
Total minimum payments	\$ 42,709
Less imputed interest	<u>(4,568)</u>
Total	<u>\$ 38,141</u>

**16. Commitments and Contingencies**

The Company is involved in certain claims, litigation, administrative proceedings and investigations relative to environmental and other matters. Although the amount of any ultimate liability which could arise with respect to these matters cannot be accurately predicted, it is the opinion of management,

**Tata Chemicals North America Inc. and Subsidiaries**  
**Notes to Consolidated Financial Statements**  
**March 31, 2026 and 2025**

---

*(in thousands)*

based upon currently available information and the accruals established that any such liability will not have a material adverse effect on the Company's financial condition, results of operations or cash flows.

**17. Subsequent Events**

The Company has evaluated subsequent events, and the impact on the reported results and disclosures, through May 26, 2026, which is the date these consolidated financial statements were available to be issued and determined no other items to disclose.

\*\*\*\*\*